title: Identification of the dopamine autoreceptor in the guinea-pig retina as D(2) receptor using novel subtype-selective antagonists.
abstract: 1. Dopamine release in the retina is subject to modulation via autoreceptors, which belong to the D(2) receptor family (encompassing the D(2), D(3) and D(4) receptors). The aim of the present study was to determine the receptor subtype (D(2) vs D(3)) involved in the inhibition of dopamine release in guinea-pig retinal discs, using established (haloperidol, (S)-nafadotride) and novel dopamine receptor antagonists (ST-148, ST-198). 2. hD(2L) and hD(3) receptors were expressed in CHO cells and the pK(i) values determined in binding studies with [(125)I]-iodosulpride were: haloperidol 9.22 vs 8.54; ST-148 7.85 vs 6.60; (S)-nafadotride 8.52 vs 9.51; ST-198 6.14 vs 7.92. 3. The electrically evoked tritium overflow from retinal discs preincubated with [(3)H]-noradrenaline (which represents quasi-physiological dopamine release) was inhibited by the dopamine receptor agonists B-HT 920 (talipexole) and quinpirole (maximally by 82 and 71%; pEC(50) 5.80 and 5.83). The concentration-response curves of these agonists were shifted to the right by haloperidol (apparent pA(2) 8.69 and 8.23) and ST-148 (7.52 and 7.66). (S)-Nafadotride 0.01 microM and ST-198 0.32 microM did not affect the concentration-response curve of B-HT 920. 4. The dopamine autoreceptor in the guinea-pig retina can be classified as a D(2) receptor. ST-148 and ST-198 show an improved selectivity for D(2) and D(3) receptors when compared to haloperidol and (S)-nafadotride, respectively.
authors.affiliation: Institut für Pharmakologie und Toxikologie, Universität Bonn, Reuterstr. 2b, 53113 Bonn, Germany.
authors.forename: B
authors.initials: B
authors.lastname: Weber
authors.forename: E
authors.initials: E
authors.lastname: Schlicker
authors.forename: P
authors.initials: P
authors.lastname: Sokoloff
authors.forename: H
authors.initials: H
authors.lastname: Stark
mesh_terms: D000818:Animals; D001381:Azepines / Q000378:metabolism / Q000494:pharmacology; D001665:Binding Sites; D016466:CHO Cells; D006224:Cricetinae; D004298:Dopamine / Q000378:metabolism; D018491:Dopamine Agonists / Q000378:metabolism / Q000494:pharmacology; D018492:Dopamine Antagonists / Q000737:chemistry / Q000378:metabolism / Q000494:pharmacology; D065127:Dopamine D2 Receptor Antagonists; D006168:Guinea Pigs; D006220:Haloperidol / Q000378:metabolism / Q000494:pharmacology; D008297:Male; D009281:Naphthalenes / Q000378:metabolism / Q000494:pharmacology; D009638:Norepinephrine / Q000378:metabolism; D011759:Pyrrolidines / Q000378:metabolism / Q000494:pharmacology; D019257:Quinpirole / Q000378:metabolism / Q000494:pharmacology; D017448:Receptors, Dopamine D2 / Q000819:agonists / Q000032:analysis* / Q000378:metabolism; D012160:Retina / Q000737:chemistry* / Q000187:drug effects* / Q000378:metabolism; D013379:Substrate Specificity
chemical_list: D001381:Azepines; D018491:Dopamine Agonists; D018492:Dopamine Antagonists; D065127:Dopamine D2 Receptor Antagonists; D009281:Naphthalenes; D011759:Pyrrolidines; D017448:Receptors, Dopamine D2; D019257:Quinpirole; C024763:talipexole; D006220:Haloperidol; C097285:nafadotride; D004298:Dopamine; D009638:Norepinephrine